FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
Go back to FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers| (NASDAQ: FBLG) | Delayed: 0.76 +0.01 (1.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.75 | 52 Week High | $ | |||
| Open | $0.75 | 52 Week Low | $ | |||
| Day High | $0.78 | P/E | N/A | |||
| Day Low | $0.75 | EPS | $ | |||
| Volume | 133,748 | |||||
